Epithelial Ovarian Cancer Market Segmentation Detailed Study with Forecast to 2025

Epithelial ovarian cancer is a disease in which malignant cells develop in the tissue that covers the ovary. Epithelial ovarian cancer is common in women who have a close relation such as mother, daughter, or sister diagnosed with the disease. In case of women having two or more blood relatives with ovarian cancer, the risk of developing the disease is higher. The hereditary information is carried from one generation to another through carrier genes received from parents. It has been estimated that hereditary ovarian cancer is approximately 5% - 10% more prevalent when compared to other cases of ovarian cancer.

Symptoms of epithelial ovarian cancer include pain in the pelvis area, swelling in the abdomen, and gastrointestinal problems such as bloating, etc. Diagnosis of epithelial ovarian cancer is conducted through a series of procedures such as pelvic examination, ultrasound, CA 125 assay, barium enema, intravenous pyelogram (IVP), CT scan, and biopsy.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33701

Epithelial ovarian cancer starts from the surface layer of the ovary. It has been estimated by the Cancer Research UK that 90% of the diagnosed ovary cancers are of this type. The epithelial ovarian cancer market can be classified on the basis of types of epithelial ovarian cancer, diagnostic techniques, and treatment methods. On the basis of type, the epithelial ovarian cancer market can be segmented into five categories: stage I, stage II, stage III, and stage IV. According to the Cancer Research UK, serous epithelial ovarian cancer accounts for two-third of the epithelial ovarian cancer diagnosed every year, while 10% of the epithelial ovarian cancer diagnosed are of undifferentiated type. Different types of treatments are available for patients suffering from epithelial ovarian cancer such as surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.

In surgery, the uterus, cervix, fallopian tubes, ovaries, and omentum are removed from the body which may include. Post-surgery, patients are treated with radiation therapy and chemotherapy in order to kill the remaining tumor cells. Primary drugs used for the chemotherapy of epithelial ovarian cancer patients include BEP, carboplatin-taxon, gemcitabine-cisplatin, and VeIP. In addition to these, two other therapies for the treatment of epithelial ovarian cancer are under clinical trials such as biologic therapy and targeted therapy.

Biologic therapy uses the patient’s immune system to fight against cancer, while targeted therapy involves the usage of drugs that identify and kill cancer-affected cells without causing any harm to the normal cells. Bevacizumab and PARP inhibitors are two such drugs under clinical trials for targeted therapy. Other major drugs under clinical trials include trebananib, paclitaxel, CVac, cositecan, and trabectadin.

According to the National Cancer Institute, in U.S., 22,240 new cases were diagnosed with ovarian cancer and the disease was responsible for 14,030 deaths. Such high rate of incidence and mortality is driving the epithelial ovarian cancer market. Asia Pacific represents the highest opportunity for epithelial ovarian cancer market owing to the increase in number of epithelial ovarian cancer and rise in awareness about the disease. Statistics released by the Cancer Australia revealed that in 2010, there were 1,305 new cases of ovarian cancer in Australia and around 1,470 and 1,640 new cases of ovarian cancer were predicted to be diagnosed in 2014 and 2020, respectively.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33701

Increase in incidences of ovarian cancer, rise in research and development in drugs, favorable reimbursement provisions in developed and developing economies, development in healthcare infrastructure, and surge in government initiatives to promote research and awareness about the disease are projected to drive the epithelial ovarian cancer market during the forecast period. However, the high cost of treatment, stringent regulation in drug testing, and lack of skilled professionals for early diagnosis of disease are anticipated to hinder the growth of the market.

The global epithelial ovarian cancer market can be divided into five geographical region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the epithelial ovarian cancer market, followed by Europe, due to high prevalence of the disease and extensive research and development activities. Increase in incidences of ovarian cancer is expected to drive the global epithelial ovarian cancer market in Asia Pacific during the forecast period.

Latin America and Middle East & Africa region are also anticipated to provide lucrative opportunities to the epithelial ovarian cancer market in the next few years. It can be largely ascribed to the growing biopharmaceutical industry in the region and the rise in participation of private players for expanding their geographical presence.

Major players in the epithelial ovarian cancer market include Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc., Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Synta Pharmaceuticals Corp., Prima BioMed, Ltd., Oasmia Pharmaceutical AB, and Glycotope GmbH.

Obtain Report Details @ https://www.transparencymarketresearch.com/epithelial-ovarian-cancer-market.html

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.